Efficacy and safety of risedronate sodium in treatment of postmenopausal osteoporosis

Abstract

To evaluate the efficacy and safety of risedronate sodium in treatment of postmenopausal osteoporosis, one-year randomized, double blind clinical trial was performed among 54 women with postmenopausal osteoporosis. The changes were compared in bone mineral density (BMD), bone metabolism markers and adverse events after 12 months oral administration of risedronate sodium. BMD was measured by dual energy X-ray absorptionmetry (DEXA) and bone turnover marker was detected. The results showed that there was a significant increase in BMD of the lumbar spine (3.29%±1.18%, 4.51%±1.64% respectively) after 6 and 12 months in the risedronate treatment group versus placebo control group (−0.62%±0.24%, 0.48%±0.18% respectively). Bone turnover was decreased to a stable nadir over 6 and 12 months for resorption markers [N-telopeptide (NTx),P<0.05] and over 12 months for formation marker (ALP,P<0.05; BGP,P<0.05). The safety profile of risedronate sodium was similar to that of placebo. There were no trends toward increased frequency of any adverse experience except for gastrointestinal symptoms (7.1%), rash (7.1%) and hematuria (3.6%), which were usually mild, transient, and resolved with continued treatment. It was concluded that risedronate was an efficacious and safe drug in treatment of postmenopausal osteoporosis.

Keywords

risedronate sodium / postmenopausal osteoporosis / bone mineral density

References

[1] BorahB, DufresneT E, ChmielewskiP A, et al. . Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone, 2004, 34(4): 736-736

[2] HarringtonJ T, Ste-MarieL G, BrandiM L, et al. . Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int, 2004, 74(2): 129-129

[3] FogelmanI, RibotC, SmithR, et al. . Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. J Clin Endocrinol Metab, 2000, 85: 1895-1895

[4] RozkydalZ, JanicekP. The effect of alendronate in the treatment of postmenopausal osteoporosis. Bratisl Lek Listy, 2003, 104(10): 309-309

[5] LufkinE G, SarkarS, KulkarniP M, et al. . Antiresorptive treatment of postmenopausal osteoporosis: review of randomized clinical studies and rationale for the Evista alendronate comparison (EVA) trial. Curr Med Res Opin, 2004, 20(3): 351-351

[6] KimmelD B, JeeW S. A quantitative histologic study of bone turnover in young adult beagles. Anat Rec, 1982, 203: 31-31

[7] GattiD, AdamiS. New bisphosphonates in the treatment of bone disease. Drugs Aging, 1999, 15: 285-285

[8] GiulianiN, PedrazzoniM, PasseriG, et al. . Bisphosphonates inhibit IL-6 production by human osteoblastliks cells. Scand J Rheumatol, 1998, 27: 38-38

[9] FleischH. Bisphosphonates: mechanisms of action. Endo Revi, 1998, 19: 80-80

[10] LuckmanS P, HughsD E, CoxonF P, et al. . Netrogencontaining bisphosphonates inhabit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including ras. J Bone Miner Res, 1998, 13: 1668-1668

[11] RossP D, KressB C, ParsonR E, et al. . Serum bone alkaline phosphatase and calcaneus bone density predict factors: A prospective study. Osteopors Int, 2000, 11(1): 76-76

[12] Dresner-pollakR, KarmeliF, EliakinR, et al. . Increased urinary N-telopetide cross-linked type I collagen predicts bone loss in patients with inflammatory bowel disease. Am J Gastroenterol, 2000, 95(3): 699-699

[13] HamiltonB, McCoyK, TaggartH. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int, 2003, 14(3): 259-259